About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Advertisement

Medindia » Health Press Releases A-Z

A Hypertension Drug Requiring Less-Frequent Dosing Than Novartis's Diovan/Tareg Would Earn Similar Patient Share in Europe and U.S.

Advertisement

The Fixed-Dose Combination Telmisartan/Amlodipine Will Become the New Decision Resources Clinical Gold Standard for Hypertension in 2013


For more information, contact:

Decision Resources	Decision Resources, Inc.
Gisselle Morales	Elizabeth Marshall
781-296-2691	781-296-2563
[email protected]	[email protected]

Sponsored Post and Backlink Submission

Latest Press Release on Hypertension News

Global Pulmonary Hypertension Community 'United for' World PH Day 2024

World pulmonary hypertension community to unite on May 5 to raise awareness, offer support and advocate for PH. WASHINGTON , April 24, 2024 /PRNewswire-PRWeb/ -- The Pulmonary...

Nonprofit Organization to Award Funds for the Research of Pulmonary Hypertension

Team PHenomenal Hope (Team PH) seeks submissions for its PHenomenal Impact Fund for Global PH Research, marking the sixth consecutive year of funding innovative studies in pulmonary hype...

First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)

INCHEON, South Korea , Feb. 7, 2024 /PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class tr...

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation

SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel , Jan. 31, 2024 /PRNewswire/ -- SoniVie , an Israeli company developing a novel, proprieta...

Research into the burden of pulmonary hypertension published by Team PHenomenal Hope

Team PHenomenal Hope, a nonprofit advocacy organization, has published a research paper in Pulmonary Circulation titled "Patient perspectives on pulmonary hypertension in the United Sta...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close